We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Spit Test Detects Breast Cancer in Five Seconds

By LabMedica International staff writers
Posted on 19 Feb 2024

Breast cancer is the most commonly diagnosed cancer worldwide, with over 2. More...

3 million new cases and approximately 685,000 deaths reported in 2020. Currently, mammography, ultrasound, MRI, and biopsies are the primary methods for diagnosing breast cancer. Despite their effectiveness, these techniques have several drawbacks, such as high costs, limited accessibility, potential inaccuracies in early detection in young women with dense breast tissue, invasiveness, and radiation exposure risks, especially for radiation-sensitive patients. Given the increasing prevalence of breast cancer in women, there is an urgent need for more innovative and efficient detection methods. Now, a saliva test that screens for breast cancer is showing promising results in experimental testing.

Developed collaboratively by researchers from the University of Florida (Gainesville, FL, USA) and National Yang Ming Chiao Tung University (Hsinchu City, Taiwan), this innovative hand-held device can detect breast cancer biomarkers using just a small saliva sample. The device operates by applying saliva to a test strip treated with specific antibodies that react to cancer biomarkers. It then sends electrical impulses to contact points on the biosensor, measuring signals that are converted into digital data, indicating the level of biomarkers present. This method provides rapid and easily interpretable results.

In trials, the device successfully differentiated between healthy breast tissue, early-stage breast cancer, and advanced breast cancer in a group of 21 women. The non-invasive test could be completed in less than a minute, including the application of a 3–5 μl saliva sample onto the strip, with each test performed 10 times within 15 milliseconds. The design of this biosensor incorporates common elements like glucose testing strips and the Arduino open-source hardware-software platform, making it user-friendly and promising for broad public use in the future.

Related Links:
University of Florida 
Yang Ming Chiao Tung University 


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Automated Coagulation Analyzer
Hemolumi H6
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study validated a genetic scoring tool designed to help physicians diagnose idiopathic pulmonary fibrosis and stratify risk for severe outcomes, including death or lung transplantation (Image Credit: Adobe Stock)

Genetic Risk Score Supports Diagnosis and Prognosis in Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) causes progressive, irreversible lung scarring that limits breathing and can lead to death. More than 100,000 Americans live with IPF, and an estimated 30,000–40,000... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image

Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms

Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more

Industry

view channel
Im

Eurobio Scientific Completes Acquisition of CareDx Lab Products Division

Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.